S-palmitoylation of c-MET by CK2α-mediated zDHHC15 phosphorylation drives glioblastoma stem cell tumorigenicity
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noaf098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Yang Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Glioblastoma, Proto-Oncogene Proteins c-met, Neoplastic Stem Cells, Acyltransferases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Jiangsu Province Hospital.
Abstract (Originalsprache)
Background
The c-MET signaling pathway is crucial for the self-renewal and tumorigenic capacity of cancer stem cells, including glioblastoma stem cells (GSCs). Despite its recognized importance, the precise mechanisms of c-MET activation in these cells remain elusive. This study aimed to elucidate the key regulatory elements and mechanisms governing c-MET function in GSCs.
Methods
The mediation of S-palmitoylation and dimerization of c-MET by zDHHC15 was validated using metabolic labeling, acyl-PEG exchange (APE), BS3 crosslinking, and co-immunoprecipitation. The role of the CK2α-zDHHC15-c-MET axis in tumorigenesis, along with the antitumor efficacy of TVB-3166, was confirmed through cell proliferation, limiting dilution, and intracranial tumor growth assays.
Results
We revealed that zDHHC15, a member of the DHHC family of palmitoyl acyltransferases, mediates the palmitoylation of c-MET at Cys801, which is critical for c-MET O-glycosylation, dimerization, and activation. We further identified a novel regulatory loop in which CK2α phosphorylates zDHHC15 at Tyr92, increasing its stability and c-MET binding, thereby enhancing c-MET palmitoylation. zDHHC15 was found to be specifically enriched in GSCs, and its targeted knockdown markedly impaired their self-renewal and tumorigenic capabilities both in vitro and in vivo. Therapeutically, we introduced TVB-3166, an inhibitor of c-MET S-palmitoylation, which demonstrated robust inhibitory effects on GSC growth in orthotopic xenograft models.
Conclusions
This study establishes the CK2α-zDHHC15-c-MET axis as a pivotal regulatory hub in GSC maintenance and identifies c-MET S-palmitoylation as a novel and promising therapeutic target for the treatment of glioblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Institute for Brain Tumors, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
ORCID-Profile: Huibo Wang
Förderung
- National Natural Science Foundation of China
- Jiangsu Province Hospital
Zitieren
APA
Wang, Y., Chen, Z., Li, R., Wei, D., Wang, S., Luo, H., Tu, Y., Liu, C., Xu, H., Xu, J., Ding, M., Meng, M., Fu, T., Ding, Y., Yin, J., Wu, W., Ji, J., & Wang, H. (2025). S-palmitoylation of c-MET by CK2α-mediated zDHHC15 phosphorylation drives glioblastoma stem cell tumorigenicity. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf098
Vancouver
Wang Y, Chen Z, Li R, Wei D, Wang S, Luo H, et al. S-palmitoylation of c-MET by CK2α-mediated zDHHC15 phosphorylation drives glioblastoma stem cell tumorigenicity. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf098
BibTeX
@article{Wang2025,
author = {Wang, Yang and Chen, Zhengxin and Li, Rui and Wei, Dong and Wang, Shuai and Luo, Hui and Tu, Yiming and Liu, Cen and Xu, Haibiao and Xu, Jiachen and Ding, Mingtian and Meng, Minghui and Fu, Tao and Ding, Yangyin and Yin, Jun and Wu, Wei and Ji, Jing and Wang, Huibo},
title = {S-palmitoylation of c-MET by CK2α-mediated zDHHC15 phosphorylation drives glioblastoma stem cell tumorigenicity},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noaf098}
}
EUVIMED